Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,665 | 855 | 88.0% |
| Education | $2,014 | 16 | 11.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86.93 | 6 | 0.5% |
| Gift | $43.45 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,172 | 145 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,483 | 99 | $0 (2024) |
| Cadwell Industries, INC | $1,185 | 3 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $1,113 | 43 | $0 (2024) |
| EMD Serono, Inc. | $933.19 | 44 | $0 (2024) |
| UCB, Inc. | $757.52 | 49 | $0 (2024) |
| Genentech USA, Inc. | $717.45 | 49 | $0 (2024) |
| Biogen, Inc. | $690.05 | 48 | $0 (2024) |
| Allergan, Inc. | $619.52 | 43 | $0 (2022) |
| Amgen Inc. | $519.09 | 32 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,620 | 115 | ABBVIE INC. ($1,288) |
| 2023 | $3,021 | 144 | ABBVIE INC. ($974.34) |
| 2022 | $3,825 | 161 | Cadwell Industries, INC ($1,185) |
| 2021 | $1,473 | 55 | Celgene Corporation ($319.22) |
| 2020 | $444.97 | 26 | Novartis Pharmaceuticals Corporation ($98.31) |
| 2019 | $1,828 | 117 | Allergan Inc. ($264.59) |
| 2018 | $2,071 | 124 | Biogen, Inc. ($288.63) |
| 2017 | $2,525 | 136 | Teva Pharmaceuticals USA, Inc. ($291.60) |
All Payment Transactions
878 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $0.84 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $10.51 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $32.73 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: Neurology | ||||||
| 12/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.86 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $32.60 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/18/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $11.49 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: Neurology | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Neurology | ||||||
| 11/05/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $27.09 | General |
| Category: PAIN | ||||||
| 10/29/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $6.53 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/21/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Immunology | ||||||
| 10/15/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $1.43 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/07/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $38.40 | General |
| Category: EPILEPSY | ||||||
| 10/07/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: NEUROSCIENCE | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: Neurology | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $0.09 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 2,326 | 3,680 | $1.5M | $412,833 |
| 2022 | 26 | 2,019 | 3,328 | $1.3M | $353,391 |
| 2021 | 22 | 1,963 | 3,452 | $1.1M | $317,538 |
| 2020 | 21 | 2,187 | 4,409 | $1.3M | $365,430 |
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95715 | Measurement of brain wave activity with video (veeg), 12-26 hours with intermittent monitoring | Office | 2023 | 45 | 131 | $393,000 | $84,671 | 21.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 166 | 170 | $157,590 | $50,223 | 31.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 210 | 642 | $150,870 | $49,698 | 32.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 208 | 406 | $127,890 | $37,658 | 29.4% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 115 | 115 | $89,125 | $25,879 | 29.0% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2023 | 163 | 173 | $67,470 | $16,662 | 24.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 110 | 113 | $58,195 | $14,209 | 24.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 58 | 244 | $16,950 | $11,747 | 69.3% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 67 | 69 | $41,745 | $11,561 | 27.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $35,573 | $10,913 | 30.7% |
| 95700 | Measurement of brain wave activity (eeg), continuous | Office | 2023 | 49 | 50 | $38,000 | $10,268 | 27.0% |
| 92546 | Test for abnormal eye movement using a rotating chair | Office | 2023 | 94 | 94 | $28,090 | $9,323 | 33.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 89 | $24,297 | $8,948 | 36.8% |
| 95724 | Measurement of brain wave activity with video (veeg), 61-84 hours with review and report by health care professional | Office | 2023 | 32 | 32 | $32,064 | $8,045 | 25.1% |
| 92540 | Evaluation and testing for balance with recording | Office | 2023 | 94 | 94 | $24,675 | $7,930 | 32.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 90 | $18,180 | $6,190 | 34.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 95 | 123 | $18,450 | $5,364 | 29.1% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 28 | 128 | $9,300 | $5,037 | 54.2% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 28 | 128 | $9,110 | $4,872 | 53.5% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 12 | 28 | $18,312 | $4,507 | 24.6% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 29 | 29 | $14,718 | $3,994 | 27.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 63 | $13,986 | $3,873 | 27.7% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 24 | 102 | $7,650 | $3,804 | 49.7% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 26 | 52 | $29,640 | $3,224 | 10.9% |
| 92548 | Test for balance and posture | Office | 2023 | 77 | 77 | $19,250 | $2,890 | 15.0% |
About Paul Janda, DO, JD
Paul Janda, DO, JD is a Neurology healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/25/2008. The National Provider Identifier (NPI) number assigned to this provider is 1497924468.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Paul Janda, DO, JD has received a total of $17,809 in payments from pharmaceutical and medical device companies, with $2,620 received in 2024. These payments were reported across 878 transactions from 71 companies. The most common payment nature is "Food and Beverage" ($15,665).
As a Medicare-enrolled provider, Janda has provided services to 8,495 Medicare beneficiaries, totaling 14,869 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Las Vegas, NV
- Active Since 02/25/2008
- Last Updated 02/13/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1497924468
Products in Payments
- BOTOX (Biological) $1,589
- QULIPTA (Drug) $1,334
- KESIMPTA (Drug) $925.11
- UBRELVY (Drug) $520.80
- TYSABRI (Biological) $518.29
- Briviact (Drug) $477.79
- Aimovig (Biological) $449.07
- APTIOM (Drug) $442.46
- OCREVUS (Biological) $423.76
- ACTHAR (Biological) $414.58
- ZEPOSIA (Drug) $384.56
- NURTEC ODT (Drug) $332.76
- AUSTEDO (Drug) $317.20
- MAYZENT (Drug) $284.02
- MAVENCLAD (Drug) $263.66
- NUPLAZID (Drug) $262.12
- LEMTRADA (Drug) $251.67
- AUBAGIO (Drug) $250.87
- Rebif (Biological) $250.59
- UPLIZNA (Drug) $231.51
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Las Vegas
Mr. Zoltan Mari, Md, MD
Neurology — Payments: $557,878
Le Hua, M.d, M.D
Neurology — Payments: $527,646
Dr. Abraham Nagy, M.d, M.D
Neurology — Payments: $314,938
Dr. Carrie Hersh, D.o, D.O
Neurology — Payments: $311,872
Dr. Fan Zhang, Do, DO
Neurology — Payments: $257,387
Dr. Nicole Theuvenet, M.d, M.D
Neurology — Payments: $220,553